BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com) Chairman and CEO, Jeff Morhet will host a webcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)’s efficacy in reducing the growth rate of lymphoma cancer tumors.
